TRIAL DETAIL

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

Drug:
Trial Name:
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
NCT#:
Conditions:
Chronic Myeloproliferative Disorders; Gastrointestinal Stromal Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; ...
Status:
Completed
Phase:
1
Start Date 10/01/2001
Age of Trial (yrs) 23.2
Treatment Phase:
First-line
Drug Category:
KIT/PDGFRA inhibitor
Strategy:
Block KIT
Trial Type:
Specifically GIST plus other cancers
Other Protocol IDs:
CDR0000068959, PCI-01-028, MB-NAVY-B01-053, NCI-02-C-0020, NCI-5331
Sponsor:
UPMC Cancer Center, NCI
Patient Contact:
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:

Trial Links

Trial Results
 

Drug Information
All About Gleevec (LRG website)
 
Gleevec prescribing information
 
Patient assistance program (insurance, financial help, etc).
 
Gleevec blood level monitoring (LRG story/info)
 
Gleevec drug interactions (LRG site)
 
Gleevec.com website (GIST portion)
 
FDA approves adjuvant Gleevec
 
Effect of a proton pump inhibitor on the pharmacokinetics of imatinib
 
Imatinib Mesylate May Improve Fasting Blood Glucose in Diabetic Ph+ Chronic Myelogenous Leukemia Patients Responsive to Treatment
 
European Commission approves new label for Novartis drug Glivec® extending adjuvant therapy to three years for certain GIST patients
 
Disintegration of chemotherapy tablets (including imatinib) for oral administration in patients with swallowing difficulties
 
Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor.
 

Trial Sites

Name
Address
City
State
Zip
Country